Can Gilead end the AIDS pandemic by opening access to Lenacapavir?

Question

Accepted Answer

Gilead can significantly advance the end of the AIDS pandemic by opening access to Lenacapavir.

Gilead could bring the AIDS pandemic closer to an end by allowing broader access to its HIV drug, Lenacapavir. The head of UNAIDS, Winnie Byanyima, has urged the pharmaceutical company to enable generic manufacturing of this twice-yearly injectable antiretroviral medication. By making cheaper versions available in low- and middle-income nations, the drug could reach more individuals in need.
Lenacapavir's Potential Impact on HIV Treatment and Prevention

Lenacapavir, approved in the US and EU in 2022, represents a significant advancement in HIV treatment, offering a twice-yearly injectable option. Its high effectiveness places it in a distinct category of preventive medicines, making it particularly valuable for populations who face challenges accessing daily oral therapies. The drug is also undergoing testing for pre-exposure prophylaxis (PrEP) with promising initial results, suggesting it could play a dual role in both treatment and prevention.
Call for Generic Manufacturing and Tiered Pricing

UNAIDS is advocating for Gilead to license Lenacapavir to the UN-backed Medicines Patent Pool. This mechanism would facilitate the production of more affordable generic versions for distribution in low- and middle-income countries. Byanyima has suggested that a tiered pricing strategy could allow Gilead to maintain profitability while ensuring wider accessibility, a model that has proven successful with other essential medicines.
Global Efforts to End AIDS by 2030

The call for increased access to Lenacapavir aligns with UNAIDS' ambitious goal to end HIV as a public health threat by 2030. While significant progress has been made in expanding access to antiretroviral therapy, with approximately 30 million people currently receiving treatment, an estimated 10 million individuals still require access. By leveraging innovative treatments like Lenacapavir and implementing equitable access strategies, the global community can move closer to achieving this target.

Reading history

Hide →

This history is cleared when the page is closed.

Can Gilead end the AIDS pandemic by opening access to Lenacapavir?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends